We identified relevant studies on serotype replacement in disease with a comprehensive search of PubMed (by use of combinations of the search terms “pneumococ*”, “Streptococcus pneumoniae”, “PCV7”, “conjugate”, and “serotype”) and the reference lists of selected articles. Because we were interested in the question of population-wide serotype dynamics, we included only studies that reported the incidence of vaccine-type and NVT disease in the general population (ie, nationwide or hospital-based
ReviewSerotype replacement in disease after pneumococcal vaccination
Introduction
Widespread use of heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar, Wyeth, Madison, NJ, USA) has significantly reduced the burden of pneumococcal disease in many populations.1, 2, 3, 4, 5, 6, 7, 8 PCV7 targets seven of the more than 92 serotypes (so-called “vaccine types”) of Streptococcus pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F), whereas the newly available PCV13 covers these seven serotypes as well as serotypes 1, 3, 5, 6A, 7F, and 19A. PCV7 has greatly reduced the incidence of disease caused by these serotypes both in vaccinated young children and among non-vaccinated groups due to herd immunity, and has led to public health benefits throughout the developed world where it has been used. In light of this evidence and of clinical trials done in developing countries that show substantial benefits,9, 10, 11 conjugate vaccines are being introduced more widely throughout the world. However, the epidemiological effect of broad-scale use of conjugate vaccines in new settings can be difficult to predict, so careful monitoring of disease burden will be needed to assess the initial and long-term effects of mass vaccination in each region where the vaccine is introduced.
The pneumococcal population has changed since the widespread introduction of PCV7. Non-vaccine types (NVTs) have increased among asymptomatic carriers in a process dubbed “serotype replacement”,12, 13 and to a lesser extent, NVTs have increased as causes of invasive pneumococcal disease (IPD). In nasopharyngeal carriage, we define serotype replacement as an increase in the proportion of individuals in a population who harbour NVTs in their nasopharynx after vaccine introduction. For IPD, serotype replacement is defined as an increase in the incidence of IPD caused by NVTs after vaccine introduction. Although the reported magnitude of this increase in disease among NVTs has been relatively modest in most countries, such changes have the potential to dampen the overall public-health benefit of the vaccine.
A key question is why does serotype replacement seem to be complete among asymptomatic carriers whereas replacement in disease seems incomplete? In other words, why has the vaccine successfully reduced the burden of pneumococcal disease whereas the prevalence of bacterial carriage has not changed? Understanding this issue will be crucial to enable us to predict the effects of future pneumococcal vaccination programmes, particularly in developing countries where pneumococcal epidemiology differs from that in Europe and the USA. We therefore review the evidence for serotype replacement in carriage and disease, assess potential biases in the data and reasons for heterogeneity between studies, discuss the biological and epidemiological features of the serotypes, and address the relative contributions of vaccination and other factors to the increases in NVTs. We also discuss the potential effects of serotype replacement after the introduction of conjugate vaccines in diverse settings.
Section snippets
Nasopharyngeal carriage: the precursor to IPD
The first reports of serotype replacement came from a double-blind, randomised placebo-controlled trial (RCT) from The Gambia that showed that carriage of vaccine types significantly declined in vaccinated infants, while carriage of NVTs significantly increased.14 As a result of this change, the net effect on carriage prevalence in the trial was small. An Israeli vaccine trial did not show a significant effect of serotype replacement in carriage among vaccinated children,15 but a subsequent
Background
Many studies have assessed serotype-specific IPD incidence before and after the introduction of PCV7 (table), but the measured effect of vaccination on NVT disease has been inconsistent. In classic, individually randomised trials, only a small proportion of the population is typically vaccinated. Therefore, such trials have a small effect on the overall bacterial population by contrast with what will occur with mass vaccination. For this reason, individually randomised trials are not designed
Background
Now that we have reviewed the evidence for serotype replacement in carriage and disease, we return to the questions of why serotype replacement has been complete in carriage but not in disease, how much the incidence of IPD has truly been affected by vaccination and replacement, and what factors are likely to be responsible for the increase in NVTs.
Discrepancy in magnitude of replacement between carriage and disease
The incidence of IPD caused by a particular serotype is the product of the incidence rate of new carriage episodes with that serotype, and the
Vaccination in developing countries
The studies reviewed here show that despite the increased incidence of NVTs that cause IPD in many populations, PCV7 has had a significant positive benefit on paediatric disease, especially in children younger than 2 years, in whom it is in widespread use. The measured benefit clearly varies across populations; some of this variation is real, and indicates host and pathogen population characteristics. The epidemiology of IPD in developing countries differs from that in other parts of the world.
Future prospects for serotype replacement in disease
The evidence presented here strongly support the notion that serotype replacement has occurred in IPD in most populations and is caused by the vaccine. We should assume that the introduction of new conjugate vaccine formulations in the future will again be met with complete serotype replacement among carriers and some amount of replacement in disease that will partly depend on the invasiveness of the colonising serotypes. The recently introduced 13-valent vaccine has the potential to have
Search strategy and selection criteria
References (108)
- et al.
Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme
Vaccine
(2010) - et al.
Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule
Vaccine
(2010) - et al.
The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007
Vaccine
(2010) - et al.
Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany
Vaccine
(2009) - et al.
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
Lancet
(2005) - et al.
Prevention of pneumococcal disease by vaccination: does serotype replacement matter?
Lancet
(2000) - et al.
Carriage of pneumococci after pneumococcal vaccination
Lancet
(1996) - et al.
Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France
Vaccine
(2010) - et al.
Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine
Clin Microbiol Infect
(2009) - et al.
An easy method for detection of nasopharyngeal carriage of multiple Streptococcus pneumoniae serotypes
J Microbiol Methods
(2008)
Impact of a single dose of the 7-valent pneumococcal conjugate vaccine on colonization
Vaccine
Epidemiology of pediatric community-acquired bloodstream infections in a children hospital in Paris, France, 2001 to 2008
Diagn Microbiol Infect Dis
Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain
Clin Microbiol Infect
Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine
Clin Microbiol Infect
Changes in serotypes causing invasive pneumococcal disease (2005–2007 vs 1997–1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine
Clin Microbiol Infect
Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine
Clin Microbiol Infect
Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000–2006
Vaccine
Incidence of invasive pneumococcal disease among children after introduction of a 7-valent pneumococcal conjugate vaccine: a population-based study in Olmsted County, Minnesota
Mayo Clinic Proc
Trends in invasive pneumococcal disease among older adults in Olmsted County, Minnesota
J Infect
National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential
Vaccine
Changes of serotype and genotype in Streptococcus pneumoniae isolates from a Korean hospital in 2007
Diagn Microbiol Infect Dis
Design of a group-randomized Streptococcus pneumoniae vaccine trial
Control Clin Trials
Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation?
Vaccine
Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete
Epidemics
The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model
Vaccine
Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006
J Infect
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
J Infect Dis
Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007
Clin Infect Dis
Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine
Pediatr Infect Dis J
Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands
Emerg Infect Dis
Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial
Pediatr Infect Dis J
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
N Engl J Med
Vaccination against colonizing bacteria with multiple serotypes
Proc Natl Acad Sci USA
Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
J Infect Dis
Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers
J Infect Dis
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
J Infect Dis
Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial
JAMA
Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine
J Infect Dis
Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings
Pediatr Infect Dis J
Continued impact of pneumococcal conjugate vaccine on serotypes, antibiotic resistance, and risk factors for carriage in young children
Pediatrics
Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway
Clin Vaccine Immunol
Trends in nasopharyngeal carriage of Streptococcus pneumoniae among children attending daycare centers in southeastern France from 1999 to 2006
Pediatr Infect Dis J
Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece
Pediatr Infect Dis J
Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life
Clin Infect Dis
Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease
J Infect Dis
Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes
Am J Epidemiol
Detection of Streptococcus pneumoniae strain cocolonization in the nasopharynx
J Clin Microbiol
Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae
Pediatr Infect Dis J
Multiplex PCR reveals a high rate of nasopharyngeal pneumococcal 7-valent conjugate vaccine serotypes co-colonizing indigenous Warao children in Venezuela
J Med Microbiol
Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community randomized trial
J Infect Dis
Cited by (751)
Targeting bacterial polysaccharides with antibodies and vaccines
2024, Methods in MicrobiologyStreptococcus pneumoniae serotype 19A in hospitalized children with invasive pneumococcal disease after the introduction of conjugated vaccines in Lima, Peru
2024, Journal of Infection and Public HealthIn silico design of an epitope-based vaccine against PspC in Streptococcus pneumoniae using reverse vaccinology
2023, Journal of Genetic Engineering and Biotechnology